Positive preliminary results with Biodel's new insulin formulation in type 2 diabetes
Endocrine specialists Biodel (Nasdaq: BIOD) has seen positive preliminary results from a Phase IIa trial of its insulin formulation BIOD-531.
The trial compared BIOD-531 to Humalog Mix 75/25 and Humulin R U-500 (both products from Eli Lilly) in patients with type 2 diabetes with moderate insulin resistance, taking between 50 and 200 units of insulin per day.
It found that BIOD-531 was associated with superior glucose control compared to Humalog Mix 75/25 throughout the day of observation, and was also associated with superior glucose control compared to Humulin R U-500. The duration of glucose lowering was monitored by giving subjects a standardized lunch at 330 minutes after breakfast dosing with no insulin administered at that time, and glucose levels being measured every five minutes during the 720 minutes after test insulin dosing at breakfast.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze